Stock listing
Lang & Schwarz:A414VY Tvardi Therapeutics, Inc. Aktie
German listing (Lang & Schwarz) of Tvardi Therapeutics, Inc. · home listing NASDAQ:TVRD
Follow Tvardi Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:TVRD
$0.989 USD -0.051 (-4.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:TVRD
- Day range
- $0.900 – $1.000 USDNov 20, 2026
- Volume
- 159,935 sharesNov 20, 2026
- Market cap
- $13.22M USDAt the close on Nov 20, 2026 · price × 13.36M shares outstanding
- 52-week range
- $0.773 – $5.690 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $315,657 USDMedian day 126,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TVRD · Home | $0.989 USD | -0.051 (-4.9%) | 159,935 | $0.920 | $1.000 | $0.900 | $1.040 | Close on Nov 20, 2026 |
| Frankfurt:69C | €0.78 EUR | +0.04 (+5.4%) | — | €0.71 | €0.78 | €0.71 | €0.74 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TVRD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.989 | -0.051 | -4.9% | $0.920 | $1.000 | $0.900 | 159,935 | |
| $1.040 | +0.030 | +3.0% | $1.020 | $1.100 | $0.970 | 69,049 | |
| $1.010 | -0.090 | -8.2% | $1.071 | $1.080 | $1.010 | 71,181 | |
| $1.100 | -0.080 | -6.8% | $1.170 | $1.170 | $1.060 | 49,027 | |
| $1.180 | +0.025 | +2.2% | $1.140 | $1.180 | $1.080 | 74,174 | |
| $1.155 | -0.185 | -13.8% | $1.300 | $1.300 | $1.150 | 166,780 | |
| $1.340 | -0.070 | -5.0% | $1.400 | $1.610 | $1.260 | 458,300 | |
| $1.410 | 0.000 | 0.0% | $1.390 | $1.530 | $1.310 | 548,300 | |
| $1.410 | +0.452 | +47.2% | $0.960 | $1.610 | $0.958 | 4,591,800 | |
| $0.958 | +0.093 | +10.8% | $0.857 | $0.980 | $0.847 | 55,300 | |
| $0.865 | +0.004 | +0.5% | $0.870 | $0.882 | $0.810 | 176,500 | |
| $0.861 | +0.026 | +3.1% | $0.819 | $0.889 | $0.805 | 50,000 | |
| $0.835 | +0.030 | +3.7% | $0.830 | $0.890 | $0.796 | 93,100 | |
| $0.805 | +0.012 | +1.5% | $0.826 | $0.850 | $0.790 | 94,900 | |
| $0.793 | -0.070 | -8.1% | $0.868 | $0.928 | $0.773 | 154,900 | |
| $0.863 | -0.024 | -2.7% | $0.890 | $0.915 | $0.850 | 111,500 | |
| $0.887 | +0.022 | +2.5% | $0.840 | $0.927 | $0.840 | 86,100 | |
| $0.865 | +0.023 | +2.7% | $0.831 | $0.900 | $0.831 | 72,700 | |
| $0.842 | -0.098 | -10.4% | $0.940 | $0.970 | $0.842 | 139,400 | |
| $0.940 | -0.032 | -3.3% | $1.070 | $1.070 | $0.920 | 108,300 | |
| $0.972 | -0.048 | -4.7% | $1.010 | $1.050 | $0.972 | 55,400 | |
| $1.020 | +0.028 | +2.8% | $1.020 | $1.090 | $1.000 | 136,800 | |
| $0.992 | +0.022 | +2.3% | $1.030 | $1.076 | $0.970 | 195,200 | |
| $0.970 | -0.040 | -4.0% | $1.010 | $1.028 | $0.969 | 201,300 | |
| $1.010 | -0.060 | -5.6% | $1.050 | $1.069 | $1.000 | 91,800 | |
| $1.070 | +0.070 | +7.0% | $1.030 | $1.070 | $1.000 | 94,000 | |
| $1.000 | -0.040 | -3.8% | $1.010 | $1.030 | $0.990 | 75,700 | |
| $1.040 | -0.020 | -1.9% | $1.060 | $1.060 | $1.012 | 73,400 | |
| $1.060 | +0.030 | +2.9% | $1.020 | $1.080 | $0.970 | 248,100 | |
| $1.030 | -0.050 | -4.6% | $1.090 | $1.090 | $1.020 | 130,300 | |
| $1.080 | -0.020 | -1.8% | $1.100 | $1.100 | $1.040 | 159,900 | |
| $1.100 | +0.020 | +1.9% | $1.080 | $1.110 | $1.040 | 136,500 | |
| $1.080 | -0.060 | -5.3% | $1.150 | $1.180 | $1.070 | 148,300 | |
| $1.140 | -0.010 | -0.9% | $1.170 | $1.170 | $1.120 | 148,300 | |
| $1.150 | -0.090 | -7.3% | $1.250 | $1.277 | $1.130 | 313,800 | |
| $1.240 | -0.010 | -0.8% | $1.250 | $1.310 | $1.210 | 332,600 | |
| $1.250 | -0.030 | -2.3% | $1.290 | $1.320 | $1.200 | 232,700 | |
| $1.280 | -0.050 | -3.8% | $1.320 | $1.420 | $1.260 | 254,100 | |
| $1.330 | +0.060 | +4.7% | $1.270 | $1.370 | $1.190 | 351,300 | |
| $1.270 | +0.210 | +19.8% | $1.140 | $1.280 | $1.070 | 656,600 | |
| $1.060 | -0.260 | -19.7% | $1.300 | $1.330 | $0.930 | 609,400 | |
| $1.320 | -0.250 | -15.9% | $1.590 | $1.610 | $1.255 | 412,100 | |
| $1.570 | -0.040 | -2.5% | $1.620 | $1.730 | $1.570 | 125,400 | |
| $1.610 | -0.020 | -1.2% | $1.650 | $1.660 | $1.570 | 186,100 | |
| $1.630 | +0.010 | +0.6% | $1.630 | $1.658 | $1.590 | 121,600 | |
| $1.620 | -0.110 | -6.4% | $1.720 | $1.743 | $1.610 | 193,100 | |
| $1.730 | -0.030 | -1.7% | $1.740 | $1.805 | $1.730 | 126,700 | |
| $1.760 | -0.070 | -3.8% | $1.830 | $1.836 | $1.735 | 112,200 | |
| $1.830 | -0.040 | -2.1% | $1.890 | $2.000 | $1.810 | 170,100 | |
| $1.870 | +0.035 | +1.9% | $1.830 | $1.940 | $1.830 | 115,400 | |
| $1.835 | -0.015 | -0.8% | $1.830 | $1.900 | $1.810 | 77,500 | |
| $1.850 | -0.090 | -4.6% | $1.920 | $1.940 | $1.850 | 95,000 | |
| $1.940 | +0.030 | +1.6% | $1.910 | $1.959 | $1.870 | 164,100 | |
| $1.910 | +0.060 | +3.2% | $1.850 | $1.920 | $1.810 | 73,300 | |
| $1.850 | -0.030 | -1.6% | $1.890 | $1.910 | $1.840 | 98,500 | |
| $1.880 | +0.135 | +7.7% | $1.750 | $1.880 | $1.750 | 107,600 | |
| $1.745 | -0.055 | -3.1% | $1.810 | $1.840 | $1.745 | 96,000 | |
| $1.800 | -0.020 | -1.1% | $1.820 | $1.840 | $1.755 | 117,400 | |
| $1.820 | +0.020 | +1.1% | $1.800 | $1.919 | $1.780 | 337,300 | |
| $1.800 | +0.020 | +1.1% | $1.790 | $1.840 | $1.780 | 70,900 | |
| $1.780 | -0.040 | -2.2% | $1.820 | $1.830 | $1.760 | 87,500 | |
| $1.820 | +0.040 | +2.2% | $1.790 | $1.890 | $1.785 | 77,100 | |
| $1.780 | -0.080 | -4.3% | $1.870 | $1.870 | $1.770 | 63,400 | |
| $1.860 | +0.030 | +1.6% | $1.830 | $1.930 | $1.820 | 166,800 | |
| $1.830 | -0.050 | -2.7% | $1.870 | $1.890 | $1.820 | 126,100 |
Splits
2 splits since 2024 · NASDAQ:TVRD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-3 | Consolidation | |
| 1-for-12 | Consolidation |
- Ticker
- Lang & Schwarz:A414VY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 63 slides
Latest news
Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback
Nov 19, 2026
Closed $0.989 (-4.9%) on Nov 20, 2026
Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
Nov 13, 2026
Closed $1.18 (+2.2%) on Nov 13, 2026
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
Oct 14, 2026
Closed $1.00 (-3.8%) on Oct 14, 2026
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Aug 14, 2026
Closed $1.90 (+7.3%) on Aug 14, 2026
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
Aug 12, 2026
Closed $1.77 (+0.6%) on Aug 12, 2026
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
Jul 30, 2026
Closed $2.10 (-1.9%) on Jul 30, 2026
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Jul 7, 2026
Closed $3.10 (+54.2%) on Jul 7, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Events
May 21, 2026
Closed $3.59 (-6.8%) on May 21, 2026
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
May 8, 2026
Closed $4.18 (-0.7%) on May 8, 2026
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
Apr 2, 2026
Closed $3.02 (+0.7%) on Apr 2, 2026
Tvardi Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 102 in all · newest Nov 19, 2026 · oldest 2021
- Calls
- 14 calls with a replay · 14 with a transcript · latest Mar 4, 2024
- Decks
- 11 decks · latest September 2026
Where Tvardi Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TVRD · Home listing | NASDAQ | United States | USD |
| Lang & Schwarz:A414VY · This page | Lang & Schwarz | Germany | EUR |
| LS Exchange:A414VY | LS Exchange | Germany | EUR |
| Frankfurt:69C | Frankfurt | Germany | EUR |
| gettex:69C | gettex | Germany | EUR |
| Tradegate:69C | Tradegate | Germany | EUR |
| Stuttgart:69C0 | Stuttgart | Germany | EUR |
| LSE:0HTC | LSE | United Kingdom | USD |
| BOATS:TVRD | BOATS | United States | USD |
| BX Swiss:TVRD | BX Swiss | Switzerland | CHF |
| Munich:69C | Munich | Germany | EUR |
Valuation
Price/book 0.9× against a median of 2.7×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$9.05M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.89
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics, Inc. · NASDAQ:TVRD | US$13.22M | −US$9.05M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.89 |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS | US$13.49M | −US$38.84M | n/a | n/a | n/a | 0.4× | n/a | 0.8× | 1.45 |
| Pharma Equity Group A/S Class A · OMXCOP:PEG | US$13.47M | US$15.05M | n/a | n/a | 52.8× | 3.6× | n/a | 0.4× | n/a |
| BioInvent International AB · OMXSTO:BINV | US$13.45M | −US$6.62M | n/a | −1.7× | n/a | 0.7× | n/a | 0.1× | n/a |
| Thalia Therapeutics PLC · LSE:THAT | US$13.36M | US$11.39M | n/a | 1,199× | n/a | 4.2× | n/a | 0.0× | n/a |
| Celyad Oncology SA · EURONEXT:CYAD | US$13.31M | US$13.21M | 14.6× | 573× | n/a | 9.7× | n/a | 0.0× | n/a |
| Defence Therapeutics Inc Class A · CSE:DTC | US$13.27M | US$13.16M | n/a | n/a | n/a | 5.4× | n/a | 0.5× | 0.74 |
| Diamyd Medical AB Class B · OMXSTO:DMYD_B | US$13.22M | −US$16.66M | n/a | −357× | n/a | 0.6× | n/a | 0.0× | n/a |
| Devonian Health Group, Inc. · TSXV:GSD | US$13.09M | US$12.59M | n/a | 6.0× | n/a | 2.7× | −204.1% | 0.0× | 0.12 |
| Median of the others | US$13.40M | US$12.05M | 7.5× | 6.0× | 52.8× | 2.7× | −204.1% | 0.0× | 1.31 |
Forecasts
5 strong buy · 2 buy · 1 hold · 1 sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.88 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.25 · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Imran Alibhai | Chief Executive Officer |
| Dan Conn | Chief Financial Officer |
| Kari Anne Rowland | Vice President, Clinical Operations |
| Sofia de Achaval | Vice President, Development |
| Stephen O’Brien | VP, Finance and Corporate Controller |
| Yixin Joseph Chen | Vice President, CMC |
| David Tweardy | Co-Founder |
| John Kauh | Chief Medical Officer |
| Michael T. Lewis | Co-Founder & Professor, Molecular and Cellular Biology and Radiology |
| Ron DePinho | Co-Founder & Chairman of Scientific Advisory Board |
Board
| Director | Role |
|---|---|
| Ron DePinho | Co-Founder & Chairman of Scientific Advisory Board |
| Sujal Shah | Chairman of the Board |
| Cynthia Smith | Board Member |
| David Tweardy | Co-Founder |
| Imran Alibhai | Chief Executive Officer |
| Michael T. Lewis | Co-Founder & Professor, Molecular and Cellular Biology and Radiology |
| Michael Wyzga | Board Member |
| Susan Shiff | Board Member |
| Wallace Hall | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Cara Therapeutics, Inc. (CARA) Q4 2023 Earnings Call | Mon, Mar 04, 2024 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q3 2023 Earnings Call | Mon, Nov 13, 2023 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q2 2023 Earnings Call | Mon, Aug 07, 2023 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call | Mon, May 15, 2023 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q4 2022 Earnings Call | Mon, Mar 06, 2023 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q3 2022 Earnings Call | Mon, Nov 07, 2022 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q2 2022 Earnings Call | Mon, Aug 08, 2022 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q1 2022 Earnings Call | Mon, May 09, 2022 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q4 2021 Earnings Call | Tue, Mar 01, 2022 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q3 2021 Earnings Call | Mon, Nov 08, 2021 · 4:30 PM ET | Replay |
All 14 calls
| Call | When | Status |
|---|---|---|
| Cara Therapeutics, Inc. (CARA) Q2 2021 Earnings Call | Mon, Aug 09, 2021 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q1 2021 Earnings Call | Mon, May 10, 2021 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q4 2020 Earnings Call | Thu, Feb 25, 2021 · 4:30 PM ET | Replay |
| Cara Therapeutics, Inc. (CARA) Q3 2020 Earnings Call | Mon, Nov 09, 2020 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · Before open | +2.2% |
| Q2 2026 | Aug 14, 2026 · Before open | +7.3% |
| Q1 2026 | May 8, 2026 | −5.9% |
| Q4 2025 | Mar 31, 2026 · After close | −5.7% |
| Q3 2025 | Nov 13, 2025 · After close | −1.9% |
| Q2 2025 | Aug 14, 2025 · After close | +0.9% |
| Q1 2025 | May 13, 2025 · After close | −0.7% |
| Q4 2024 | Feb 26, 2025 | −3.6% |
| Q3 2024 | Nov 29, 2024 | +1.0% |
| Q2 2024 | Aug 5, 2024 | +4.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 | +1.1% |
| Q4 2023 | Mar 4, 2024 | −4.2% |
| Q3 2023 | Nov 13, 2023 | +4.3% |
| Q2 2023 | Aug 7, 2023 | −6.1% |
| Q1 2023 | May 15, 2023 | +11.3% |
| Q4 2022 | Mar 6, 2023 | −34.9% |
| Q3 2022 | Nov 7, 2022 | +3.6% |
| Q2 2022 | Aug 8, 2022 | +4.8% |
| Q1 2022 | May 9, 2022 | +14.7% |
| Q4 2021 | Mar 1, 2022 | +11.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 63 slides | September 2026 |
| Technical Presentation (August 2026) | Technical | 38 slides | Aug 19, 2026 |
| Investor Presentation (July 2026) | Investor deck | 63 slides | Jul 30, 2026 |
| Investor Presentation (July 2026) | Investor deck | 56 slides | Jul 7, 2026 |
| Investor Presentation (January 2026) | Investor deck | 36 slides | Jan 16, 2026 |
| Investor Presentation (November 2025) | Investor deck | 28 slides | Nov 19, 2025 |
| Investor Presentation (June 2025) | Investor deck | 38 slides | Jun 9, 2025 |
| Cara Therapeutics — Merger or Acquisition (April 2025) | Merger or acquisition | 37 slides | Apr 11, 2025 |
| Cara Therapeutics — Merger or Acquisition (January 2025) | Merger or acquisition | 36 slides | Jan 21, 2025 |
| Cara Therapeutics — Merger or Acquisition (December 2024) | Merger or acquisition | 31 slides | Dec 20, 2024 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Cara Therapeutics — Merger or Acquisition (December 2024) | Merger or acquisition | 31 slides | Dec 18, 2024 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares Closed: US$28M raised Use of proceeds: With both companies' cash, to fund the combined company's operating expenses and capital expenditures into the second half of 2026 | Dec 18, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Cara Therapeutics, Inc. Priced at US$11.00 a share on Jan 30, 2014.
- Price
- US$11.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$55 million
- Underwriters' option
- Up to 750,000 more shares
- Underwriters
- Stifel, Piper Jaffray, Canaccord Genuity, Needham & Company, Janney Montgomery Scott · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 4, 2013 |
| Filed publicly | Nov 8, 2013 |
| Amended twice | Newest Jan 17, 2014 |
| Shares registered with an exchange | Jan 27, 2014 |
| Declared effective by the SEC | Jan 30, 2014 |
| Final prospectus, with the price | Feb 3, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 3, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Jan 30, 2014 |
| EFFECT · Notice that a registration is effective | Jan 30, 2014 |
| CORRESP · Letter to the SEC | Jan 28, 2014 |
| CORRESP · Letter to the SEC | Jan 28, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 27, 2014 |
| S-1/A · Registration statement, amended | Jan 17, 2014 |
| S-1/A · Registration statement, amended | Dec 31, 2013 |
| CORRESP · Letter to the SEC | Dec 30, 2013 |
| UPLOAD · Letter from the SEC | Nov 21, 2013 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Nov 8, 2013 |
| S-1 · Registration statement | Nov 8, 2013 |
| UPLOAD · Letter from the SEC | Nov 1, 2013 |
| DRS · Draft registration statement | Oct 4, 2013 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 3, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 7.14M | 21.0M | 41.9M | 23.0M | 135.1M | 19.9M | 13.5M | 911.0K | 86.0K |
| Cost of revenue | 95.0K | 812.0K | 6.43M | 7.51M | 0 | |||||
| Gross profit | -95.0K | 6.33M | 14.5M | 34.4M | 21.5M | |||||
| Research and development | 18.0M | 23.6M | 108.5M | 91.9M | 82.7M | 107.9M | 113.8M | 75.5M | 48.5M | 49.3M |
| Selling, general and administrative | 8.74M | 4.46M | 2.80M | 2.73M | ||||||
| Operating income | -26.7M | -28.1M | -121.5M | -87.5M | -89.1M | 5.38M | -111.7M | -77.4M | -59.5M | -58.4M |
| Depreciation and amortization | 95.0K | 95.0K | 259.0K | 248.0K | 248.0K | 209.0K | 198.0K | 370.0K | 495.0K | 1.47M |
| EBITDA | -26.7M | -28.0M | -121.2M | -87.3M | -88.8M | 5.59M | -111.5M | -77.0M | -59.0M | -56.9M |
| Interest expense | 8.47M | 0 | 3.00K | |||||||
| Income before tax | -18.2M | -71.3M | -118.5M | -85.5M | -88.4M | 7.72M | -107.2M | -74.4M | -58.3M | -57.7M |
| Income tax | 0 | 0 | 0 | 0 | 0 | -691.0K | -816.0K | -389.0K | -204.0K | -468.0K |
| Net income | -18.2M | -29.4M | -118.5M | -85.5M | -88.4M | 8.41M | -106.4M | -74.0M | -58.1M | -57.3M |
| Earnings per share, basic | -2.46 | -11.42 | -26.26 | -19.12 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.10 |
| Earnings per share, diluted | -3.26 | -11.42 | -26.26 | -19.12 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.10 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 20.7M | 31.6M | 51.8M | 63.7M | 13.5M | 31.7M | 18.3M | 15.1M | 9.39M | 12.1M |
| Short-term investments | 10.1M | 0 | 49.0M | 22.3M | 153.6M | 149.2M | 136.7M | 146.3M | 83.2M | 46.2M |
| Receivables | 407.0K | 2.77M | 3.26M | 1.15M | 2.06M | |||||
| Inventory | 900.0K | 2.82M | 2.38M | 2.58M | ||||||
| Current assets | 31.5M | 31.7M | 116.2M | 168.9M | 173.3M | 195.1M | 165.7M | 168.1M | 95.1M | 61.4M |
| Property, plant and equipment | 52.0K | 84.0K | 3.32M | 426.0K | 631.0K | 840.0K | 700.0K | 880.0K | 1.18M | 1.61M |
| Total assets | 32.1M | 35.2M | 125.8M | 182.2M | 247.1M | 271.2M | 233.0M | 190.8M | 97.0M | 63.8M |
| Accounts payable | 3.22M | 2.19M | 11.6M | 9.60M | 5.63M | 4.89M | 9.10M | 4.37M | 3.83M | 4.74M |
| Current liabilities | 11.0M | 10.4M | 25.6M | 23.5M | 17.6M | 18.5M | 42.9M | 40.4M | 8.51M | 11.5M |
| Long-term debt | 30.3M | |||||||||
| Total debt | 201.0K | 44.4M | 368.0K | 2.37M | 3.67M | 5.28M | ||||
| Total liabilities | 11.1M | 40.8M | 68.8M | 23.5M | 19.5M | 22.2M | ||||
| Shareholders' equity | 20.9M | -91.1M | -62.1M | 158.8M | 227.5M | 249.0M | 186.7M | 133.6M | 86.8M | 50.7M |
| Shares outstanding | 9.38M | 2.57M | 4.54M | 53.8M | 53.5M | 49.9M | 46.7M | 39.5M | 32.7M | 27.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.5M | -18.3M | -92.1M | -78.7M | -60.1M | -5.49M | -109.2M | -22.3M | -54.8M | -47.4M |
| Capital spending | 0 | -1.05M | -2.38M | -43.0K | -39.0K | -349.0K | -18.0K | -73.0K | -58.0K | -717.0K |
| Free cash flow | -23.5M | -19.4M | -94.5M | -78.8M | -60.1M | -5.84M | -109.2M | -22.4M | -54.9M | -48.1M |
| Cash from investing | -10.1M | 48.7M | 43.5M | 128.7M | -4.75M | -20.3M | -30.5M | -82.8M | -36.5M | 45.0M |
| Cash from financing | 22.7M | 27.0M | 38.2M | 311.0K | 46.6M | 39.1M | 142.6M | 110.8M | 87.9M | 123.0K |
| Change in cash | -10.9M | 8.70M | -10.5M | 50.3M | -18.2M | 13.4M | 2.86M | 5.69M | -2.70M | -3.01M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 19, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jul 17, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 14, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 13, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | May 8, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 8, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Results | SEC |
| UPLOAD · Letter from the SEC | May 7, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 1, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Apr 1, 2026 | Offer document | SEC |
| POS EX | Apr 1, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 1, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 424B3 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 16, 2026 | Current report | SEC |
| 8-K · Current report | Dec 18, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 19, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 13, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Oct 20, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Oct 20, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| S-1/A · Registration statement, amended | Oct 7, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 14, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 9, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jun 5, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 2, 2025 | Big-stake notice | SEC |
| S-1 · Registration statement | May 30, 2025 | Offer document | SEC |
| 8-K · Current report | May 27, 2025 | Current report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 8-K/A · Current report, amended | May 13, 2025 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | May 2, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 2, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 2, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 2, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 22, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 15, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Apr 11, 2025 | Current report | SEC |
| 8-K · Current report | Apr 1, 2025 | Meeting outcome | SEC |
| 425 | Mar 24, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 24, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| SEC STAFF LETTER | Feb 19, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 18, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Feb 14, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 14, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Feb 14, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| S-4/A · Registration statement, amended | Jan 27, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 24, 2025 | Other filings | SEC |
| 425 | Jan 21, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 425 | Jan 17, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 17, 2025 | Current report | SEC |
| SEC STAFF LETTER | Jan 17, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 16, 2025 | Other filings | SEC |
| 425 | Dec 30, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 30, 2024 | Current report | SEC |
| 425 | Dec 20, 2024 | Other filings | SEC |
| 8-K/A · Current report, amended | Dec 20, 2024 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 18, 2024 | Big-stake notice | SEC |
| S-4 · Registration statement | Dec 18, 2024 | Offer document | SEC |
| 425 | Dec 18, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 18, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 22, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Oct 30, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 1, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 18, 2024 | Current report | SEC |
| 8-K · Current report | Jun 12, 2024 | Current report | SEC |
| 424B5 · Prospectus | Jun 7, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 7, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 4 · Change in ownership | May 6, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 22, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 12, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 22, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 2, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 29, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 22, 2024 | Current report | SEC |
| 8-K · Current report | Dec 18, 2023 | Current report | SEC |
| 8-K · Current report | Nov 13, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 2, 2023 | Material contract | SEC |
| 8-K · Current report | Aug 7, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 4, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2023 | Management or board change | SEC |
This page holds 200 of 812 filings. Open Filings
Cap table
Built by 6ix from Tvardi Therapeutics, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 13,363,391
- Fully diluted
- 13,363,391
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 13,363,391 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 13,363,391 |
| Sep 30, 2026 | 13,345,956 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cynthia Smith Other companies: Agios Pharmaceuticals, Inc. (Independent Director · Since at least Aug 11, 2022); Protara Therapeutics, Inc. (Director · Since at least Jan 29, 2021); Spero Therapeutics, Inc. (Director · Since at least Mar 19, 2019); Akebia Therapeutics, Inc. (Senior Vice President, Market Access and Commercial Development · Since at least Aug 28, 2018); Dicerna Pharmaceuticals Inc (Director · Aug 13, 2018 – Dec 28, 2021 · Past); Alpine Immune Sciences Inc (Director · Nov 1, 2016 – Nov 1, 2016 · Past); ZS Pharma Inc (Chief Commercial Officer · Jun 17, 2014 – Dec 17, 2015 · Past) | Board Member · Since at least Apr 15, 2025 |
| Edward Hurwitz Other companies: Dyne Therapeutics, Inc. (Director · Since at least Jul 31, 2020); MacroGenics, Inc. (Director · Since at least Oct 9, 2013); Turmeric Acquisition Corp (Chief Financial Officer · Oct 15, 2020 – Oct 15, 2020 · Past); Sunesis Pharmaceuticals Inc (Director · Apr 3, 2009 – Jun 28, 2013 · Past) | Director · Jan 30, 2014 – Feb 5, 2014 · Past |
| Helen M. Boudreau Other companies: Rallybio Corporation (Board Member · Since at least Jul 29, 2021); Shattuck Labs, Inc. (Director · Since at least Oct 8, 2020); Kineta Inc. (Chief Financial Officer · Feb 10, 2016 – Mar 1, 2018 · Past) | Director · Aug 2, 2023 – Jun 4, 2024 · Past |
| Mani Mohindru Other companies: Cardiff Oncology, Inc. (President & Chief Executive Officer · Since at least Jun 10, 2021); CytomX Therapeutics, Inc. (Director · Since at least Dec 16, 2020); Curis, Inc. (Chief Strategy Officer · Jan 19, 2016 – Feb 14, 2017 · Past) | CFO & Chief Strategy Officer · Aug 15, 2017 – Dec 2, 2019 · Past |
| Martin Vogelbaum Other companies: Rocket Pharmaceuticals, Inc. (Director · Feb 17, 2015 – Jun 24, 2015 · Past); NephroGenex Inc (Director · Feb 10, 2014 – May 15, 2014 · Past); MiddleBrook Pharmaceuticals Inc (Director · Apr 20, 2007 – Jun 23, 2009 · Past) | Director · Jan 30, 2014 – Jun 4, 2024 · Past |
| Michael Wyzga Other companies: Mereo BioPharma Group plc (Director · Since at least Feb 26, 2026); X4 Pharmaceuticals, Inc. (Director · Since at least Jun 9, 2025); Kineta Inc. (See Remarks · Aug 16, 2021 – Dec 2, 2022 · Past) | Board Member · Since at least Apr 15, 2025 |
| Ryan Maynard Other companies: Foghorn Therapeutics Inc. (Chief Financial Officer · Since at least Feb 23, 2026); Iovance Biotherapeutics, Inc. (Director · Since at least Feb 16, 2015); Rigel Pharmaceuticals, Inc. (EVP & CFO · May 27, 2010 – Nov 3, 2017 · Past) | CHIEF FINANCIAL OFFICER · Sep 12, 2022 – Feb 8, 2024 · Past |
| Lisa von Moltke Other companies: Zenas BioPharma, Inc. (Head of Research and Development and Chief Medical Officer · Since at least Mar 17, 2025); Seres Therapeutics, Inc. (See Remarks · Apr 6, 2020 – Feb 15, 2025 · Past) | Director · Nov 1, 2022 – Jun 4, 2024 · Past |
| Harrison M Bains Jr Other companies: BG Medicine Inc (Director · Jun 12, 2013 – Jun 3, 2014 · Past) | Director · Jul 16, 2014 – Jun 1, 2023 · Past |
| Jeffrey L Ives Other companies: Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021) | Director · Jul 16, 2014 – Jun 4, 2024 · Past |
All 36 people
| Person | Seat |
|---|---|
| Joana Goncalves Other companies: Oruka Therapeutics, Inc. (Chief Medical Officer · Since at least Aug 29, 2024) | CHIEF MEDICAL OFFICER · Oct 22, 2018 – Apr 5, 2024 · Past |
| Shaheen Wirk Other companies: Corvex, Inc. (Director · Since at least Jan 2, 2025) | Director · Apr 15, 2025 – Apr 17, 2025 · Past |
| Thomas Charles Reilly Other companies: Amarin Corporation plc (EVP and CFO · Jun 30, 2022 – Jul 1, 2024 · Past) | Chief Financial Officer · Oct 1, 2020 – Mar 3, 2022 · Past |
| Avi Daniel Conn | Chief Financial Officer · Since at least Apr 15, 2025 |
| Christopher Posner | PRESIDENT AND CEO, Director · Nov 2, 2023 – Feb 28, 2025 · Past |
| Dan Conn | Chief Financial Officer · Since at least Nov 4, 2026 |
| David Tweardy | Co-Founder · Since at least Nov 4, 2026 |
| Dean Slagel | Director · Jun 15, 2016 – Jun 29, 2017 · Past |
| Derek T Chalmers | President & CEO, Director · Jan 6, 2016 – Sep 7, 2021 · Past |
| Frederique Ph D Menzaghi | CHIEF SCIENTIFIC OFF,SVP-R&D · Jan 30, 2014 – Feb 1, 2024 · Past |
| Imran Alibhai | Chief Executive Officer · Since at least Apr 15, 2025 |
| Jeffrey Leroy Larson | SVP, Research & Development · Apr 15, 2025 – Apr 17, 2025 · Past |
| John Kauh | Chief Medical Officer · Since at least Apr 15, 2025 |
| Josef Schoell | Chief Financial Officer · Jan 30, 2014 – Jul 26, 2017 · Past |
| Kari Anne Rowland | Vice President, Clinical Operations · Since at least Nov 5, 2026 |
| Michael T. Lewis | Co-Founder & Professor, Molecular and Cellular Biology and Radiology · Since at least Nov 4, 2026 |
| Richard Makara | VP, Head of Accting;Controller · Jun 15, 2022 – Jun 15, 2022 · Past |
| Ron DePinho | Co-Founder & Chairman of Scientific Advisory Board · Since at least Nov 4, 2026 |
| Scott Terrillion | SEC'Y; CHIEF COMPLIANCE & G.C. · May 1, 2017 – Feb 28, 2025 · Past |
| Sofia de Achaval | Vice President, Development · Since at least Nov 5, 2026 |
| Stephen O’Brien | VP, Finance and Corporate Controller · Since at least Apr 15, 2025 |
| Sujal Shah | Chairman of the Board · Since at least Apr 15, 2025 |
| Susan Shiff | Director · Since at least Jun 26, 2020 |
| Wallace Hall | Board Member · Since at least Nov 5, 2026 |
| Wallace L Hall Jr | Director · Since at least Apr 15, 2025 |
| Yixin Joseph Chen | Vice President, CMC · Since at least Apr 15, 2025 |
Log in to ask 6ix AI your own questions about Tvardi Therapeutics, Inc.